Open the filing on EDGARLantheus Reports Third Quarter 2025 Financial Results and Provides Business Update
Recorded third quarter 2025 worldwide revenue of $384.0 million, GAAP fully diluted earnings per share of $0.41, adjusted fully diluted earnings per share of $1.27 and free cash flow of $94.7 million
Separately announced upcoming retirement of CEO, departure of President and appointment of prior CEO to Executive Chairperson; Board conducting CEO search
Announced PDUFA dates for its new formulation of piflufolastat F 18 PSMA PET imaging agent; for MK-6240, its F 18 tau-targeted positron emission tomography (PET) imaging agent; and for LNTH-2501, its Ga 68 PET diagnostic imaging kit targeting somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs)
Closed acquisition of Life Molecular Imaging in July, immediately expanding near- and long-term growth profile and commercial portfolio
Repurchased $100 million of shares of common stock in the third quarter pursuant to the previously announced stock repurchase plan that was approved by the Board in July 2025
Provided updated corporate guidance for full year 2025 revenue and adjusted fully diluted earnings per share, reflecting the Life Molecular Imaging acquisition and current business outlook
BEDFORD, Mass., November 6, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its third quarter ended September 30, 2025.
“Lantheus’ third quarter results underscore the strength of our strategy and the dedication of our team as we continue to advance our leadership in radiopharmaceuticals,” said Brian Markison, CEO. “As I look ahead to my planned retirement at year-end, announced separately today, I am confident Lantheus is set up for continued success. On the heels of this quarter’s solid results, Lantheus is preparing for the next chapter of our prostate cancer franchise by prioritizing PYLARIFY commercial execution with focus and discipline, while advancing our broader strategic diversification plan, including our new PSMA PET formulation. Together with the combined expertise of the Lantheus team and our talented Life Molecular Imaging and Evergreen colleagues, we remain united in our purpose to Find, Fight and Follow disease to deliver better patient outcomes.”
Summary Financial Results
| Three Months Ended September 30, |
|---|
| (in millions, except per share data - unaudited) | 2025 | 2024 | % Change |
| Worldwide revenue | $384.0 | $378.7 | 1.4% |
| GAAP net income | $27.8 | $131.1 | (78.8%) |
| GAAP fully diluted earnings per share | $0.41 | $1.79 | (77.1%) |
| Adjusted net income (non-GAAP) | $85.7 | $124.1 | (30.9%) |
| Adjusted fully diluted earnings per share (non-GAAP) | $1.27 | $1.70 | (25.3%) |
Third Quarter 2025
Sales of PYLARIFY were $240.6 million, a decrease of 7.4%.
Sales of DEFINITY were $81.8 million, an increase of 6.3%.
Operating income decreased 67.4% to $43.6 million. Adjusted operating income (non-GAAP) decreased 27.6% to $119.6 million.
Fully diluted earnings per share decreased 77.1% to $0.41, compared to $1.79 in the prior year period. Adjusted fully diluted earnings per share (non-GAAP) decreased 25.3% to $1.27, compared to $1.70 in the prior year period.
Net cash provided by operating activities and free cash flow were $105.3 million and $94.7 million, respectively.
Balance Sheet
At September 30, 2025, the Company's cash and cash equivalents were $382.0 million, after payments of $276.4 million and $355.2 million for the acquisitions of Evergreen Theragnostics, Inc. (“Evergreen”) and Life Molecular Imaging, respectively, and payment of $100 million for the repurchase of common stock, compared to $912.8 million at December 31, 2024.
The Company currently has access to up to $750.0 million from a revolving line of credit.
Recent Business Highlights
Leadership Transition Plan
On November 6, Lantheus announced that Chief Executive Officer Brian Markison will retire from the Company, effective December 31, 2025. Additional details on the leadership transition plan are disclosed in a separate press release and filing, available in the Investor Relations section of our website located at www.lantheus.com.
Business Development Updates
In July, the Company announced the completion of the acquisition of Life Molecular Imaging. Through the transaction, Lantheus strengthened its nuclear medicine commercial portfolio, and enhanced the company’s capabilities across the radiopharmaceutical value chain. As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Managing Director of Life Molecular Imaging, joined Lantheus as Head of Research and Development.
In September, the Company announced an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commercialize Lantheus’ piflufolastat F 18 in Japan (PYLARIFY® in the U.S. market) for prostate cancer diagnostics and companion diagnostic use. Under the terms of the agreement, GE HealthCare paid an upfront license fee and will pay Lantheus for development milestones and tiered royalties based on product sales in Japan.
Radiopharmaceutical Pipeline Updates
In October, the Company announced the FDA established a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2026 for LNTH-2501 (Gallium-68 edotreotide), the Company’s diagnostic kit for the preparation of Ga 68 edotreotide Injection, indicated for use with PET imaging for localization of SSTR+ NETs in adult and pediatric patients.
In October, the Company announced the FDA has accepted its New Drug Application (NDA) for MK-6240, the Company’s F 18-labeled tau-targeted PET imaging agent. MK-6240 previously received Fast Track designation from the FDA for its potential to address an unmet medical need in Alzheimer’s disease diagnostics. The FDA has set a PDUFA target action date of August 13, 2026.
In August, the Company announced the FDA acceptance of its NDA for a new formulation of piflufolastat F 18 PSMA PET imaging agent. In addition to increasing batch size - potentially enabling increased patient access, supply resilience, and enhanced production efficiency - Lantheus anticipates that the new formulation will qualify for three years of transitional pass-through payment status. The FDA has set a PDUFA target action date of March 6, 2026.
Other Key Updates
Full Year 2025 Updated Corporate Financial Guidance
| Guidance Issued November 6, 2025 | Guidance Issued August 6, 2025 |
|---|
| FY 2025 Revenue | $1.49 billion - $1.51 billion | $1.475 billion - $1.51 billion |
| FY 2025 Adjusted fully diluted EPS | $5.50 - $5.65 | $5.50 - $5.70 |
On a forward-looking basis, the Company does not provide GAAP income per common share guidance or a reconciliation of GAAP income per common share to adjusted fully diluted EPS because the Company is unable to predict with reasonable certainty business development and acquisition related expenses, purchase accounting fair value adjustments, and any one-time, non-recurring charges. These items are uncertain, depend on various factors, and could be material to results computed in accordance with GAAP. As a result, it is the Company’s view that a quantitative reconciliation of adjusted fully diluted EPS on a forward-looking basis is not available without unreasonable effort.
Conference Call and Webcast
As previously announced, the Company will host a conference call and webcast on Thursday, November 6, 2025, at 8:00 a.m. ET. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events.
A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days.
The conference call will include a discussion of non-GAAP financial measures. Reference is made to the most directly comparable GAAP financial measures, the reconciliation of the differences between the two financial measures, and the other information included in this press release, our Form 8-K filed with the SEC today, or otherwise available in the Investor Relations section of our website located at www.lantheus.com.
The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the safe-harbor section of this press release.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit www.lantheus.com.
Internet Posting of Information
The Company routinely posts information that may be important to investors in the “Investors” section of its website at www.lantheus.com. The Company encourages investors and potential investors to consult its website regularly for important information about the Company.
Non-GAAP Financial Measures
The Company uses non-GAAP financial measures, such as adjusted net income and its line components; adjusted net income per share - fully diluted; adjusted operating income, and free cash flow. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. However, these measures may exclude items that may be highly variable, difficult to predict and of a size that could have a substantial impact on the Company’s reported results of operations for a particular period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.
Safe Harbor for Forward-Looking and Cautionary Statements
Forward-looking statements notice
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by their use of terms such as “advance,” “believe,” “continue,” “could,” “driving,” “expect,” “guidance,” “maintain,” “may,” “on track,” “plan,” “potential,” “predict,” “progress,” “should,” “target,” “will,” “would” and other similar terms. Such forward-looking statements include our guidance for the fiscal year 2025 and our plans to expand our portfolio of late-stage assets and high potential early-stage candidates, our acquisitions of Evergreen and Life Molecular Imaging and our plans to divest our SPECT business to SHINE Technologies, LLC (“SHINE”), a wholly owned subsidiary of Illuminated Holdings, Inc., and are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: (i) continued market expansion and penetration for our established commercial products, particularly PYLARIFY, DEFINITY and Neuraceq, in a competitive environment and our ability to clinically and commercially differentiate our products; (ii) our ability to have third parties manufacture our products and our ability to manufacture DEFINITY in our in-house manufacturing facility, in amounts and at the times needed; (iii) the availability of raw materials, key components, and equipment, either used in the production of our products and product candidates, or by healthcare professionals (“HCPs”) of our products and product candidates, including, but not limited to positron emission tomography (“PET”) scanners for PYLARIFY, Neuraceq, MK-6240 and NAV-4694; (iv) our ability to obtain U.S. Food and Drug Administration (“FDA”) approval for our new formulation of our F-18 prostate-specific membrane antigen (“PSMA”) PET imaging agent, to complete the technology transfer across our PET manufacturing facilities (“PMF”) network for such new formulation, and to obtain adequate coding, coverage and payment, including transitional pass-through payment status (“TPT Status”), for such new formulation; (v) our ability to satisfy our obligations under our existing clinical development partnerships using MK-6240 or NAV-4694 as a research tool and under the license agreements through which we have rights to MK-6240 and NAV-4694, and to further develop and commercialize MK-6240 and NAV-4694 as approved products; (vi) our ability to successfully integrate acquisitions, including of Life Molecular and Evergreen, including the potential for unforeseen expenses related to integration activities, the accuracy of our financial models, the potential for unforeseen liabilities within those businesses, the ability to integrate disparate information technology systems, retain key talent and create a merged corporate culture that successfully realizes the full potential of the combined organization; (vii) our ability to complete the sale of our single-photon emission computerized tomography (“SPECT”) business to SHINE on the proposed terms and on the anticipated timeline, or at all, including risks and uncertainties related to securing the necessary regulatory approvals and satisfaction of other closing conditions to consummate the transaction, unforeseen expenses related to the divestiture, and failure to realize the expected benefits of the transaction; (viii) our ability to obtain FDA approval for LNTH-2501, our investigational kit for the preparation of Gallium-68 edotreotide Injection, which may be used in conjunction with a PET scan to stage and localize gastroenteropancreatic neuroendocrine tumors in adult and pediatric patients, and approval for PNT2003, and to be successful in the patent litigation associated with PNT2003; (ix) the cost, efforts and timing for clinical development, regulatory approval, adequate coding, coverage and payment and successful commercialization of our product candidates and new clinical applications and territories for our products, in each case, that we or our strategic partners may undertake; (x) our ability to identify opportunities to collaborate with strategic partners and to acquire or in-license additional diagnostic and therapeutic product opportunities in oncology, neurology and other strategic areas and continue to grow and advance our pipeline of products; (xi) the effect that changes to management, including turnover in our leadership and senior management team, could have on our business; and (xii) the risk and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).
Consolidated Statements of Operations
(in thousands, except per share data - unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, |
|---|
| 2025 | 2024 | 2025 | 2024 |
|---|
| Revenues | $384,014 | $378,734 | $1,134,823 | $1,142,800 |
| Cost of goods sold | 161,648 | 136,608 | 433,746 | 403,054 |
| Gross profit | 222,366 | 242,126 | 701,077 | 739,746 |
| Operating expenses | | | | |
| Sales and marketing | 48,828 | 43,719 | 132,372 | 134,300 |
| General and administrative | 81,898 | 40,516 | 205,229 | 135,820 |
| Research and development | 48,025 | 24,148 | 129,828 | 132,773 |
| Total operating expenses | 178,751 | 108,383 | 467,429 | 402,893 |
| Gain on sale of assets | - | - | - | 6,254 |
| Operating income | 43,615 | 133,743 | 233,648 | 343,107 |
| Interest expense | 4,950 | 4,903 | 14,671 | 14,624 |
| Investment in equity securities - unrealized gain | (1,160) | (37,325) | (871) | (75,492) |
| Other income | (2,556) | (9,953) | (23,579) | (27,785) |
| Income before income taxes | 42,381 | 176,118 | 243,427 | 431,760 |
| Income tax expense | 14,610 | 45,025 | 63,956 | 107,528 |
| Net income | $27,771 | $131,093 | $179,471 | $324,232 |
| Net income per common share: | | | | |
| Basic | $0.41 | $1.89 | $2.63 | $4.69 |
| Diluted | $0.41 | $1.79 | $2.60 | $4.55 |
| Weighted average common shares outstanding: | | | | |
| Basic | 67,230 | 69,464 | 68,132 | 69,193 |
| Diluted | 67,663 | 73,065 | 69,038 | 71,331 |
Consolidated Revenues Analysis
(in thousands, except percent data - unaudited)
| Three Months Ended | Nine Months Ended |
|---|
| September 30, | September 30, |
|---|
| 2025 | 2024 | Change $ | Change % | 2025 | 2024 | Change $ | Change % |
|---|
| PYLARIFY | $240,616 | $259,756 | $(19,140) | (7.4)% | $748,912 | $791,881 | $(42,969) | (5.4)% |
| Other radiopharmaceutical oncology | - | - | - | - % | - | 384 | (384) | (100.0)% |
| Total radiopharmaceutical oncology | 240,616 | 259,756 | (19,140) | (7.4)% | 748,912 | 792,265 | (43,353) | (5.5)% |
| DEFINITY | 81,785 | 76,965 | 4,820 | 6.3% | 244,935 | 231,629 | 13,306 | 5.7% |
| Neuraceq | 20,442 | - | 20,442 | 100.0% | 20,442 | - | 20,442 | 100.0% |
| TechneLite | 21,127 | 20,480 | 647 | 3.2% | 65,820 | 70,380 | (4,560) | (6.5)% |
| Other precision diagnostics | 6,339 | 6,282 | 57 | 0.9% | 18,672 | 18,039 | 633 | 3.5% |
| Total precision diagnostics | 129,693 | 103,727 | 25,966 | 25.0% | 349,869 | 320,048 | 29,821 | 9.3% |
| Strategic partnerships and other revenue | 13,705 | 15,251 | (1,546) | (10.1)% | 36,042 | 30,487 | 5,555 | 18.2% |
| Total revenues | $384,014 | $378,734 | $5,280 | 1.4% | $1,134,823 | $1,142,800 | $(7,977) | (0.7)% |
Reconciliation of GAAP to Non-GAAP Financial Measures
(in thousands, except per share and percent data - unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, |
|---|
| 2025 | 2024 | 2025 | 2024 |
|---|
| Net income | $27,771 | $131,093 | $179,471 | $324,232 |
| Stock and incentive plan compensation | 24,501 | 20,366 | 68,020 | 54,229 |
| Amortization of acquired intangible assets | 14,639 | 11,908 | 30,626 | 31,961 |
| Campus consolidation costs | (213) | 23 | (146) | 37 |
| Contingent consideration fair value adjustments | 982 | (1,505) | 982 | (1,405) |
| Non-recurring fees | - | - | 2,633 | - |
| Gain on sale of assets | - | - | - | (6,254) |
| Strategic collaboration and license costs | 860 | 30 | 16,273 | 66,221 |
| Investment in equity securities - unrealized gain | (1,116) | (37,325) | (785) | (75,492) |
| Acquisition, integration and divestiture-related costs | 34,973 | (263) | 62,645 | 1,346 |
| Other | 197 | 805 | (3,024) | 2,273 |
| Income tax effect of non-GAAP adjustments | (16,888) | (1,048) | (50,890) | (27,907) |
| Adjusted net income | $85,706 | $124,084 | $305,805 | $369,241 |
| Adjusted net income, as a percentage of revenues | 22.3% | 32.8% | 26.9% | 32.3% |
| Three Months Ended September 30, | Nine Months Ended September 30, |
|---|
| 2025 | 2024 | 2025 | 2024 |
|---|
| Net income per share - diluted | $0.41 | $1.79 | $2.60 | $4.55 |
| Stock and incentive plan compensation | 0.36 | 0.28 | 0.99 | 0.76 |
| Amortization of acquired intangible assets | 0.22 | 0.16 | 0.44 | 0.45 |
| Campus consolidation costs | (0.00) | 0.00 | (0.00) | 0.00 |
| Contingent consideration fair value adjustments | 0.01 | (0.02) | 0.01 | (0.02) |
| Non-recurring fees | - | - | 0.04 | - |
| Gain on sale of assets | - | - | - | (0.09) |
| Strategic collaboration and license costs | 0.01 | 0.00 | 0.24 | 0.93 |
| Investment in equity securities - unrealized gain | (0.02) | (0.51) | (0.01) | (1.06) |
| Acquisition, integration and divestiture-related costs | 0.52 | (0.00) | 0.91 | 0.02 |
| Other | 0.00 | 0.01 | (0.04) | 0.03 |
| Income tax effect of non-GAAP adjustments | (0.25) | (0.01) | (0.74) | (0.39) |
| Adjusted net income per share - diluted | $1.27 | $1.70 | $4.43 | $5.18 |
| Weighted-average common shares outstanding - diluted | 67,663 | 73,065 | 69,038 | 71,331 |
(a) Non-GAAP amount excludes a gain of $44 and $86 from the change in value of other assets for the three and nine months ended September 30, 2025, respectively.
(b) Represents the estimated income tax effect of the adjustments between GAAP net income and non-GAAP adjusted net income.
(c) Amounts may not add due to rounding.
Reconciliation of GAAP to Non-GAAP Financial Measures (Continued)
(in thousands, except per share and percent data - unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, |
|---|
| 2025 | 2024 | 2025 | 2024 |
|---|
| Operating income | $43,615 | $133,743 | $233,648 | $343,107 |
| Stock and incentive plan compensation | 24,501 | 20,366 | 68,020 | 54,229 |
| Amortization of acquired intangible assets | 14,639 | 11,908 | 30,626 | 31,961 |
| Campus consolidation costs | (213) | 23 | (146) | 37 |
| Contingent consideration fair value adjustments | 982 | (1,505) | 982 | (1,405) |
| Non-recurring fees | - | - | 2,633 | - |
| Gain on sale of assets | - | - | - | (6,254) |
| Strategic collaboration and license costs | 860 | 30 | 16,273 | 66,221 |
| Acquisition, integration and divestiture-related costs | 34,973 | (263) | 62,645 | 1,346 |
| Other | 197 | 805 | 1,703 | 2,273 |
| Adjusted operating income | $119,554 | $165,107 | $416,384 | $491,515 |
| Adjusted operating income, as a percentage of revenues | 31.1% | 43.6% | 36.7% | 43.0% |
Reconciliation of Free Cash Flow
(in thousands - unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, |
|---|
| 2025 | 2024 | 2025 | 2024 |
|---|
| Net cash provided by operating activities | $105,294 | $175,062 | $299,963 | $387,020 |
| Capital expenditures | (10,622) | (15,808) | (27,301) | (35,256) |
| Free cash flow | $94,672 | $159,254 | $272,662 | $351,764 |
| Net cash used in investing activities | $(319,468) | $(67,798) | $(615,658) | $(219,413) |
| Net cash (used in) provided by financing activities | $(99,166) | $1,869 | $(215,798) | $(14,877) |
Condensed Consolidated Balance Sheets
(in thousands - unaudited)
| September 30, | December 31, |
|---|
| 2025 | 2024 |
|---|
| Assets | | |
| Current assets: | | |
| Cash and cash equivalents | $382,006 | $912,814 |
| Accounts receivable, net | 351,376 | 321,258 |
| Inventory, net | 62,040 | 68,025 |
| Income tax receivable | 31,877 | 8,177 |
| Other current assets | 21,169 | 16,359 |
| Assets held for sale | 76,623 | - |
| Total current assets | 925,091 | 1,326,633 |
| Investment in equity securities | 46,474 | 39,489 |
| Property, plant and equipment, net | 164,072 | 176,798 |
| Intangibles, net | 739,264 | 161,761 |
| Goodwill | 240,328 | 61,189 |
| Deferred tax assets, net | 107,450 | 170,233 |
| Other long-term assets | 53,721 | 44,237 |
| Total assets | $2,276,400 | $1,980,340 |
| Liabilities and Stockholders’ Equity | | |
| Current liabilities: | | |
| Current portion of long-term debt and other borrowings | $871 | $974 |
| Accounts payable | 66,296 | 34,560 |
| Accrued expenses and other liabilities | 251,105 | 204,992 |
| Liabilities held for sale | 28,566 | - |
| Total current liabilities | 346,838 | 240,526 |
| Asset retirement obligations | 137 | 23,344 |
| Long-term debt and other borrowings, net of current portion | 567,937 | 565,279 |
| Long-term deferred tax liabilities | 55,078 | - |
| Long-term contingent consideration liabilities | 71,024 | - |
| Other long-term liabilities | 116,180 | 63,180 |
| Total liabilities | 1,157,194 | 892,329 |
| Total stockholders’ equity | 1,119,206 | 1,088,011 |
| Total liabilities and stockholders’ equity | $2,276,400 | $1,980,340 |
Contacts
Mark Kinarney
Vice President, Investor Relations
978-671-8842 ir@lantheus.com
Melissa Downs
Executive Director, External Communications
646-975-2533 media@lantheus.com